Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NGNE

Neurogene Inc

Last Close
May 09 • 01:16PM ET
33.58
Dollar change
+0.68
Percentage change
2.07 		%
Held by: VTI VXF DWAS AVSC DFAS Scroll to Statements
Index- P/E- EPS (ttm)-1.91 Insider Own10.43% Shs Outstand12.82M Perf Week-5.11%
Market Cap432.17M Forward P/E- EPS next Y-3.62 Insider Trans0.00% Shs Float11.52M Perf Month-13.30%
Income-36.32M PEG- EPS next Q-1.03 Inst Own61.84% Short Float8.58% Perf Quarter12.72%
Sales0.00M P/S- EPS this Y-231.74% Inst Trans-32.57% Short Ratio7.21 Perf Half Y154.39%
Book/sh14.51 P/B2.31 EPS next Y6.11% ROA-21.46% Short Interest0.99M Perf Year88.67%
Cash/sh15.32 P/C2.19 EPS next 5Y25.10% ROE-25.91% 52W Range12.20 - 53.00 Perf YTD73.27%
Dividend Est.- P/FCF- EPS past 5Y-16.09% ROI-18.31% 52W High-36.64% Beta1.37
Dividend TTM- Quick Ratio8.72 Sales past 5Y-20.00% Gross Margin- 52W Low175.25% ATR (14)2.56
Dividend Ex-Date- Current Ratio8.72 EPS Y/Y TTM-71.39% Oper. Margin0.00% RSI (14)45.80 Volatility8.85% 7.44%
Employees91 Debt/Eq0.08 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price51.50
Option/ShortNo / Yes LT Debt/Eq0.07 EPS Q/Q-283.53% Payout- Rel Volume0.11 Prev Close32.90
Sales Surprise- EPS Surprise349.72% Sales Q/Q- EarningsMar 18 AMC Avg Volume136.99K Price33.58
SMA200.01% SMA50-11.71% SMA20044.67% Trades Volume9,412 Change2.07%
Date Action Analyst Rating Change Price Target Change
Apr-29-24Initiated Leerink Partners Outperform $46
Mar-21-24Initiated William Blair Outperform $61
Jan-08-24Initiated H.C. Wainwright Buy $45
Jan-05-24Initiated Stifel Buy $31
Jan-04-24Initiated TD Cowen Outperform
May-07-24 06:19AM
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
(Business Wire)
Apr-22-24 04:36PM
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
(Business Wire)
Mar-20-24 05:31AM
Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023
(GuruFocus.com)
Mar-18-24 04:14PM
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
(Business Wire)
Mar-04-24 07:30AM
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
(Business Wire) +20.47%
07:30AM Loading…
Feb-29-24 07:30AM
Neurogene to Participate in Upcoming Investor Conferences
(Business Wire)
Jan-16-24 07:00AM
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
(Business Wire) +7.27%
Jan-05-24 07:00AM
Neurogene Announces Business Update and 2024 Outlook
(Business Wire) +6.50%
Dec-19-23 07:00AM
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million
(Business Wire) +8.17%
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in January 2018 and is headquartered in New York, NY.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.